肿瘤药学
腫瘤藥學
종류약학
ANTI-TUMOR PHARMACY
2013年
4期
286-289
,共4页
杨仕荣%成志红%张尊潭%黄春玲
楊仕榮%成誌紅%張尊潭%黃春玲
양사영%성지홍%장존담%황춘령
人参皂甙 Rh2%同步放化疗%中晚期宫颈癌%临床疗效
人參皂甙 Rh2%同步放化療%中晚期宮頸癌%臨床療效
인삼조대 Rh2%동보방화료%중만기궁경암%림상료효
Ginsenoside Rh2%Advanced cervical carcinoma%Concurrent chemoradiotherapy%Therapeutic effect
目的探讨人参皂甙 Rh2联合同步放化疗治疗中晚期宫颈癌的临床效果。方法选取2008年3月～2010年3月我院收治的68例中晚期宫颈癌病例，随机分为研究组（34例）和对照组（34例），研究组采用人参皂甙 Rh2联合同步放化疗方案治疗，对照组仅采用同步放化疗方案治疗。治疗结束后，观察和比较两组的近期疗效、远期疗效及不良反应。结果研究组和对照组的近期治疗总有效率分别为97.06％和94.12％，差异无统计学意义（P>0.05）；研究组的3年生存率（73.53％）、局部复发率（5.88％）和远处转移率（2.94％）与对照组相比（分别为61.76％、8.82％和8.82％），差异均无统计学意义（P>0.05）；研究组的胃肠道反应和骨髓抑制的发生率显著低于对照组（P<0.05）。结论人参皂甙 Rh2联合同步放化疗治疗中晚期宫颈癌疗效与单纯同步放化疗方案相当，但胃肠道反应和骨髓抑制等不良反应的发生率更低。
目的探討人參皂甙 Rh2聯閤同步放化療治療中晚期宮頸癌的臨床效果。方法選取2008年3月～2010年3月我院收治的68例中晚期宮頸癌病例，隨機分為研究組（34例）和對照組（34例），研究組採用人參皂甙 Rh2聯閤同步放化療方案治療，對照組僅採用同步放化療方案治療。治療結束後，觀察和比較兩組的近期療效、遠期療效及不良反應。結果研究組和對照組的近期治療總有效率分彆為97.06％和94.12％，差異無統計學意義（P>0.05）；研究組的3年生存率（73.53％）、跼部複髮率（5.88％）和遠處轉移率（2.94％）與對照組相比（分彆為61.76％、8.82％和8.82％），差異均無統計學意義（P>0.05）；研究組的胃腸道反應和骨髓抑製的髮生率顯著低于對照組（P<0.05）。結論人參皂甙 Rh2聯閤同步放化療治療中晚期宮頸癌療效與單純同步放化療方案相噹，但胃腸道反應和骨髓抑製等不良反應的髮生率更低。
목적탐토인삼조대 Rh2연합동보방화료치료중만기궁경암적림상효과。방법선취2008년3월～2010년3월아원수치적68례중만기궁경암병례，수궤분위연구조（34례）화대조조（34례），연구조채용인삼조대 Rh2연합동보방화료방안치료，대조조부채용동보방화료방안치료。치료결속후，관찰화비교량조적근기료효、원기료효급불량반응。결과연구조화대조조적근기치료총유효솔분별위97.06％화94.12％，차이무통계학의의（P>0.05）；연구조적3년생존솔（73.53％）、국부복발솔（5.88％）화원처전이솔（2.94％）여대조조상비（분별위61.76％、8.82％화8.82％），차이균무통계학의의（P>0.05）；연구조적위장도반응화골수억제적발생솔현저저우대조조（P<0.05）。결론인삼조대 Rh2연합동보방화료치료중만기궁경암료효여단순동보방화료방안상당，단위장도반응화골수억제등불량반응적발생솔경저。
Objective To explore the therapeutic effects of ginsenoside Rh2 plus concurrent chemoradiotherapy on advanced cervical cancer and its adverse reactions. Methods Sixty-eight cases of advanced cervical cancer admitted in our hospital between March, 2008 and March, 2010 were selected and randomly divided into the research group with 34 cases and control group with 34 cases. Patients in the research group were treated with ginsenoside Rh2 plus concurrent chemoradiotherapy, while patients in the control group were treated only with concurrent chemoradiotherapy. The therapeutic effects and adverse reactions were observed and evaluated after treatment. Results The effective rates of the research group and the control group were respectively 97.06% and 94.12% (P>0.05). There was no significant difference in the 3-year survival of the research group (73.53% vs. 61.76%), local recurrence rate (5.88% vs. 8.82%) and distant metastasis rate (2.94% vs. 8.82%) between the two groups (P>0.05). The incidence rates of gastrointestinal reactions and bone marrow suppression of the research group were significantly lower than those of the control group (P<0.05). Conclusion Ginsenoside Rh2 plus concurrent chemoradiotherapy was equally effective in the treatment of advanced cervical cancer compared to concurrent chemoradiotherapy alone, and the former had much lower in-cidence rates of gastrointestinal reactions and bone marrow suppression.
